| |
|
CritiTech Announces New Hires
for Filing IND
March 1, 2005
FOR IMMEDIATE RELEASE
CritiTech is pleased to announce the hiring of consultants
Dr. Amanda Radspinner and Dr. Ed Mitchell to assist the company
in filing its Investigational New Drug application to the
FDA on its drug, Nanotax. Amanda Radspinner, PhD, RAC has
ten years experience in the pharmaceutical industry both in
the US and Europe. This includes over seven years experience
with postapproval regulatory CMC submissions as well as extensive
experience in developing and preparing CMC sections for investigational
drug substances and drug products. Ed Mitchell is a PhD pharmacologist
with 30 years experience in pharmaceutical drug development.
His experience is primarily in the areas of regulatory and
product development, with a particular focus on the therapeutic
areas of oncology, cardiovascular and pulmonary/respiratory.
The company has developed Nanotax, a nanoparticulate form
of paclitaxel used to treat ovarian cancer via intraperitoneal
injection. The company plans to conduct its Phase I clinical
trials at the University of Kansas Medical Center under the
direction of Dr. Steve Williamson, oncologist, at the Medical
Center.
|
